SLC6A15 Antibody

What is SLC6A15 and why is it significant in neuroscience research?

SLC6A15 (solute carrier family 6, member 15) is a 730 amino acid multi-pass membrane protein that functions as a sodium-dependent neutral amino acid transporter. Also known as sodium-dependent neutral amino acid transporter B(0)AT2 or SBAT1, it mediates sodium-dependent, electrogenic transport of leucine and other branched chain amino acids (BCAAs) . Unlike other members of the sodium neurotransmitter symporter (SNF) family, SLC6A15 does not appear to be chloride-dependent .

SLC6A15 is predominantly expressed in the brain, specifically in a small percentage of neurons in the hippocampus, amygdala, other limbic regions, as well as the olfactory bulb, cortex, and cerebellum . Its role in amino acid transport makes it significant for understanding neuronal metabolism and potential implications in neurological disorders mapped to chromosome 12, where the SLC6A15 gene is located .

What are the key structural characteristics of SLC6A15 protein?

SLC6A15 is characterized by:

• A structure composed of twelve transmembrane domains

• A conserved ligand-binding site that facilitates amino acid transport

• Intracellular C-terminus (residues 691-705 in mouse SLC6A15)

• Multi-pass membrane configuration that enables its transport function

• A molecular weight of approximately 85 kDa when detected via Western blot

The protein's structure supports its function as a sodium-dependent transporter that specifically facilitates the movement of neutral amino acids, particularly branched-chain amino acids, across neural cell membranes .

What species reactivity can I expect from commercial SLC6A15 antibodies?

Based on sequence identity analysis, commercially available SLC6A15 antibodies show cross-reactivity with multiple species. Most antibodies available on the market are predicted to react with:

When selecting an antibody for your research, it's advisable to verify the specific reactivity claims from the manufacturer and consider validation experiments if working with species not directly tested .

What detection methods are compatible with SLC6A15 antibodies?

SLC6A15 antibodies have been successfully employed in multiple detection techniques:

• Western Blot Analysis: Detects SLC6A15 at approximately 85 kDa. Validated in mouse brain membranes, rat brain membranes, and human cell lines (HeLa, HEK293T, and Jurkat cells) .

• Immunohistochemistry (IHC): Effective for visualizing SLC6A15 expression in tissue sections, particularly in neural tissues. For example, immunohistochemical staining of mouse hippocampal CA3 region shows SLC6A15 immunoreactivity in neuronal profiles in the pyramidal layer .

• ELISA (Enzyme-Linked Immunosorbent Assay): Sandwich ELISA methods are available for quantitative measurement of SLC6A15 in human serum, plasma, cell culture supernatants, tissue homogenates, and other biological fluids .

Each method requires specific optimization of antibody concentration, incubation conditions, and detection systems for optimal results .

How can I optimize Western blot protocols for SLC6A15 detection in neural tissues?

Optimizing Western blot protocols for SLC6A15 detection in neural tissues requires attention to several critical factors:

• Sample Preparation:

  • For brain tissue, membrane preparations yield better results than whole cell lysates, as SLC6A15 is a membrane protein .

  • Use NETN lysis buffer for cell line samples, which has been validated with HeLa, HEK293T, and Jurkat cells .

  • Include protease inhibitors to prevent degradation of the target protein.

• Antibody Concentration and Incubation:

  • Start with a 1:200 dilution for most commercial anti-SLC6A15 antibodies .

  • Incubate primary antibody overnight at 4°C for optimal binding.

• Controls:

  • Include a blocking peptide control to verify specificity. Pre-incubation of the antibody with SLC6A15 blocking peptide should suppress staining .

  • Consider using tissues from different species to validate cross-reactivity (mouse and rat brain membranes have been successfully used) .

• Detection Strategy:

  • Look for the signal at approximately 85 kDa, which is the expected molecular weight for SLC6A15 .

  • If multiple bands appear, use blocking peptides to identify which band represents specific binding.

Following these guidelines should result in clear and specific detection of SLC6A15 in neural tissues, allowing for reliable quantification of expression levels .

What are the best practices for immunohistochemical localization of SLC6A15 in brain sections?

For optimal immunohistochemical localization of SLC6A15 in brain sections, consider the following protocol recommendations:

• Tissue Preparation:

  • Use perfusion-fixed frozen brain sections for best results, as this preserves the native conformation of the protein while allowing antibody access .

  • Cryosectioning at 20-30 μm thickness provides good morphological preservation and antibody penetration.

• Antibody Dilution and Incubation:

  • A 1:300 dilution of anti-SLC6A15 antibody has been successfully used in mouse and rat brain sections .

  • Incubate sections with primary antibody for 24-48 hours at 4°C to ensure thorough penetration into the tissue.

• Detection System:

  • Secondary antibody coupled to a fluorophore (such as AlexaFluor-488) provides excellent visualization of SLC6A15 immunoreactivity .

  • Counterstain nuclei with DAPI to provide anatomical context and cellular identification.

• Specificity Controls:

  • Always include a negative control by pre-incubating the antibody with a specific blocking peptide .

  • This control should show suppressed staining, confirming the specificity of the observed immunoreactivity.

• Anatomical Regions of Interest:

  • Focus on regions known to express SLC6A15, such as:

    • Hippocampal CA3 region, particularly in the pyramidal layer

    • Dorsal Raphe nucleus, where SLC6A15 immunoreactivity appears in neuronal profiles

    • Amygdala and other limbic structures

    • Olfactory bulb, cortex, and cerebellum

Following these practices should result in clear visualization of SLC6A15 expression patterns in specific neuronal populations within the brain .

How can I distinguish between SLC6A15 and other closely related transporters in my experiments?

Distinguishing SLC6A15 from other closely related transporters in the SLC6 family requires strategic experimental design:

• Antibody Selection:

  • Choose antibodies raised against unique epitopes of SLC6A15. For example, antibodies targeting the C-terminus (residues 691-705) of mouse SLC6A15 have demonstrated specificity .

  • Verify the manufacturer's validation data regarding cross-reactivity with other SLC family transporters.

• Blocking Peptide Controls:

  • Always employ SLC6A15-specific blocking peptides in parallel experiments to confirm antibody specificity .

  • A true SLC6A15 signal should be suppressed when the antibody is pre-incubated with the specific blocking peptide.

• Functional Discrimination:

  • Unlike most other SLC6 family members, SLC6A15 does not appear to be chloride-dependent, which provides a functional distinction .

  • Design transport assays that exploit this characteristic by measuring substrate transport in the presence and absence of chloride.

• Expression Pattern Analysis:

  • SLC6A15 has a distinct expression pattern, being predominantly found in a small percentage of neurons in specific brain regions .

  • Compare your results with established expression patterns to confirm identity.

• Gene Silencing Validation:

  • Use siRNA or CRISPR-Cas9 technologies targeted specifically to SLC6A15 to confirm signal specificity.

  • The signal should be diminished in knockdown or knockout samples if it truly represents SLC6A15.

By implementing these strategies, researchers can confidently distinguish SLC6A15 from other closely related transporters in the SLC6 family .

What is the significance of SLC6A15's preferential transport of branched-chain amino acids in experimental design?

SLC6A15's preferential transport of branched-chain amino acids (BCAAs) has several important implications for experimental design:

• Transport Assay Substrate Selection:

  • When designing functional assays, prioritize leucine and other BCAAs as test substrates, as these are preferentially transported by SLC6A15 .

  • Compare transport rates of BCAAs versus other amino acids to confirm functional SLC6A15 activity.

• Metabolic Studies:

  • Design metabolic tracing experiments using labeled BCAAs to track SLC6A15-mediated transport in neural tissues.

  • Consider the impact of BCAA availability on neuronal metabolism when interpreting results from SLC6A15 functional studies.

• Competitive Inhibition Approaches:

  • Leverage the transporter's BCAA preference when designing inhibition studies.

  • BCAA analogs may serve as competitive inhibitors for SLC6A15 function in experimental settings.

• Neurological Disease Relevance:

  • When studying SLC6A15 in disease models, consider how BCAA metabolism might be altered in conditions mapped to chromosome 12 .

  • Design experiments that investigate potential links between altered BCAA transport and neurological phenotypes.

• Electrophysiological Considerations:

  • Since SLC6A15 mediates electrogenic transport , include electrophysiological measurements in functional studies.

  • Design voltage-clamp experiments to measure transport-associated currents as an additional readout of SLC6A15 activity.

Understanding this substrate specificity is essential for designing meaningful functional studies and interpreting results in the context of neuronal metabolism and function .

Why might I observe multiple bands in Western blot analysis of SLC6A15?

Multiple bands in Western blot analysis of SLC6A15 can occur for several reasons:

• Post-translational Modifications:

  • SLC6A15 may undergo glycosylation or phosphorylation, resulting in bands of different molecular weights.

  • The expected molecular weight of 85 kDa may be altered by these modifications.

• Protein Degradation:

  • Incomplete protease inhibition during sample preparation can lead to partial degradation of SLC6A15.

  • This results in lower molecular weight fragments that retain antibody binding sites.

• Isoform Expression:

  • Different splice variants or isoforms of SLC6A15 may be expressed in your sample.

  • The presence of multiple isoforms would result in bands of different sizes.

• Cross-reactivity:

  • The antibody may cross-react with other members of the SLC6 family due to sequence homology.

  • To distinguish specific from non-specific binding, always include a blocking peptide control .

• Solution and Validation Approach:

  • Run parallel blots with and without pre-incubation with blocking peptide.

  • Bands that disappear with blocking peptide are likely specific for SLC6A15 .

  • Compare results across different antibodies targeting different epitopes of SLC6A15.

  • Consider mass spectrometry analysis of the different bands to confirm identity.

By systematically addressing these possibilities, you can determine which bands represent authentic SLC6A15 protein in your experimental system .

How can I troubleshoot weak or absent signals in SLC6A15 immunohistochemistry?

When facing weak or absent signals in SLC6A15 immunohistochemistry, consider these troubleshooting approaches:

• Fixation and Antigen Retrieval:

  • SLC6A15 detection works best in perfusion-fixed frozen sections rather than formalin-fixed paraffin-embedded tissues .

  • If signal is weak, attempt antigen retrieval methods (heat-induced or enzymatic) to expose epitopes that may be masked during fixation.

• Antibody Concentration Optimization:

  • If the standard 1:300 dilution yields weak signals, try a more concentrated antibody solution (1:100 or 1:200).

  • Perform a dilution series to determine the optimal concentration for your specific tissue samples.

• Incubation Conditions:

  • Extend primary antibody incubation time to 48-72 hours at 4°C for improved penetration in thick sections.

  • Consider adding protein carriers (BSA, serum) to reduce non-specific binding and improve signal-to-noise ratio.

• Detection System Enhancement:

  • Switch to a more sensitive detection system, such as tyramide signal amplification.

  • For fluorescent detection, choose a brighter fluorophore or use a confocal microscope for improved signal detection.

• Tissue-Specific Considerations:

  • Remember that SLC6A15 is expressed in only a small percentage of neurons in specific regions .

  • Ensure you are examining the correct anatomical regions (hippocampus CA3, amygdala, dorsal Raphe nucleus).

  • Use positive control tissues known to express SLC6A15 to validate your protocol.

• Antibody Quality Check:

  • Test antibody functionality by Western blot before proceeding with immunohistochemistry.

  • Consider using a different antibody if issues persist, as some epitopes may be particularly sensitive to fixation.

Implementing these strategies should help resolve weak or absent signals in SLC6A15 immunohistochemistry experiments .

What are the key considerations for quantifying SLC6A15 expression levels in comparative studies?

Accurate quantification of SLC6A15 expression in comparative studies requires attention to several methodological considerations:

• Selection of Quantification Method:

  • For protein level quantification:

    • Western blot with densitometry (for tissue or cell lysates)

    • ELISA (for more precise quantification in solution samples)

    • Immunofluorescence intensity measurement (for in situ tissue analysis)

  • For mRNA level quantification:

    • qRT-PCR with SLC6A15-specific primers

    • RNA-seq analysis

• Reference Standards and Normalization:

  • Use appropriate loading controls for Western blots (β-actin, GAPDH for whole lysates; Na⁺/K⁺-ATPase for membrane fractions)

  • For immunohistochemistry, normalize to cell count or tissue area

  • Include calibration standards for ELISA quantification

• Biological Variability Considerations:

  • SLC6A15 expression varies across brain regions

  • Expression may differ between species despite sequence homology

  • Include sufficient biological replicates (minimum n=3, preferably n≥5)

• Experimental Design for Comparative Studies:

  • Process all samples in parallel to minimize technical variation

  • Include appropriate positive and negative controls

  • Blind the analyst to experimental conditions during quantification

• Statistical Analysis Approach:

  • Choose appropriate statistical tests based on data distribution

  • Consider using ratio data rather than absolute values for more robust comparisons

  • Report both effect size and statistical significance

• Validation Across Methods:

  • Confirm key findings using at least two independent quantification methods

  • Cross-validate protein expression with mRNA expression where possible

Following these guidelines will enhance the reliability and reproducibility of comparative SLC6A15 expression studies .

How can SLC6A15 antibodies be used to investigate the transporter's role in neurological disorders?

SLC6A15 antibodies provide valuable tools for investigating this transporter's potential involvement in neurological disorders through multiple experimental approaches:

• Expression Analysis in Disease Models:

  • Use antibodies to compare SLC6A15 expression levels between healthy and diseased tissues, particularly in disorders mapped to chromosome 12 .

  • Perform immunohistochemistry to determine if SLC6A15 expression patterns are altered in specific neuronal populations in disease states .

• Association Studies with Disease Biomarkers:

  • Combine SLC6A15 immunostaining with markers of neuronal stress or neurodegeneration to assess correlations.

  • Use ELISA methods to quantify SLC6A15 levels in cerebrospinal fluid or serum as potential biomarkers .

• Functional Assessment in Patient-Derived Samples:

  • Apply antibodies to detect SLC6A15 in patient-derived neurons (from iPSCs) to study functional alterations.

  • Combine with transport assays to determine if SLC6A15-mediated BCAA transport is compromised in disease states.

• Mechanistic Studies Using Genetic Models:

  • Use antibodies to verify SLC6A15 knockdown/knockout in genetic models of neurological disorders.

  • Correlate changes in SLC6A15 expression with alterations in neuronal metabolism, particularly BCAA handling .

• Therapeutic Target Validation:

  • Apply antibodies to confirm target engagement of compounds designed to modulate SLC6A15 function.

  • Use proximity ligation assays with SLC6A15 antibodies to identify protein-protein interactions that might be therapeutically targetable.

This multifaceted approach using SLC6A15 antibodies can provide insights into the transporter's role in conditions such as hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome, and trisomy 12p-associated disorders .

What are the considerations for using SLC6A15 antibodies in co-localization studies with other neuronal markers?

When designing co-localization studies of SLC6A15 with other neuronal markers, researchers should consider:

• Antibody Compatibility Factors:

  • Host Species Selection: Choose primary antibodies raised in different host species to avoid cross-reactivity during secondary antibody detection .

  • Fixation Sensitivity: Ensure all antibodies in the multiplex panel perform well under the same fixation conditions.

  • Signal Intensity Balancing: Adjust dilutions of each antibody to achieve comparable signal intensities for accurate co-localization assessment.

• Technical Imaging Considerations:

  • Fluorophore Selection: Choose fluorophores with minimal spectral overlap to reduce bleed-through artifacts.

  • Sequential Scanning: For confocal microscopy, use sequential scanning rather than simultaneous acquisition to minimize cross-talk.

  • Optical Resolution: Use appropriate magnification and numerical aperture to resolve subcellular structures (63x or 100x oil immersion objectives recommended).

• Recommended Neuronal Markers for Co-localization:

  • Cellular Markers: NeuN (neurons), GFAP (astrocytes), Iba1 (microglia) to determine cell-type specificity

  • Subcellular Markers: MAP2 (dendrites), Tau (axons), PSD95 (postsynaptic densities) for subcellular localization

  • Functional Markers: vGlut (glutamatergic terminals), GAD67 (GABAergic neurons) for functional classification

• Quantitative Analysis Approaches:

  • Pearson's Correlation Coefficient or Manders' Overlap Coefficient for measuring degree of co-localization

  • Object-based methods for counting co-localized puncta

  • Distance-based analysis for measuring proximity without direct overlap

• Controls and Validation:

  • Single-labeled controls to set detection thresholds and check for bleed-through

  • Biological negative controls (tissues/cells not expressing one marker)

  • Cross-validation with super-resolution microscopy techniques for ambiguous cases

Following these guidelines will enhance the reliability and interpretability of co-localization studies involving SLC6A15 and other neuronal markers .

How can I develop a reliable ELISA protocol for quantifying SLC6A15 in biological samples?

Developing a reliable ELISA protocol for SLC6A15 quantification requires careful optimization of multiple parameters:

• Antibody Pair Selection:

  • Choose a capture antibody that recognizes a different epitope than the detection antibody to avoid competition .

  • Validate antibody specificity by Western blot before ELISA development .

  • Consider using a monoclonal antibody for capture and a polyclonal for detection to maximize sensitivity.

• Assay Format Optimization:

  • A sandwich ELISA format is most appropriate for SLC6A15 quantification in complex biological samples .

  • The basic workflow includes:

    • Coating plates with capture antibody

    • Blocking non-specific binding sites

    • Adding samples and standards

    • Adding detection antibody

    • Adding enzyme conjugate

    • Adding substrate and measuring signal

• Sample Preparation Guidelines:

  • For serum/plasma: Dilute samples at least 1:2 in appropriate buffer to minimize matrix effects.

  • For tissue homogenates: Use detergent-containing buffers to solubilize membrane-bound SLC6A15.

  • Include protease inhibitors in all sample preparation buffers to prevent degradation.

• Standard Curve Preparation:

  • Use recombinant SLC6A15 protein or synthetic peptide as standard.

  • Prepare a 7-8 point standard curve with 2-fold serial dilutions.

  • Include at least duplicate measurements for each standard concentration.

• Quality Control Measures:

  • Include positive and negative control samples in each assay.

  • Calculate intra-assay and inter-assay coefficients of variation (CV should be <15%).

  • Determine assay sensitivity by calculating the limit of detection and limit of quantification.

• Validation Experiments:

  • Spike-and-recovery experiments to assess accuracy

  • Dilutional linearity tests to confirm absence of matrix effects

  • Stability testing for samples under different storage conditions

By following these guidelines, researchers can develop a robust ELISA method for reliable quantification of SLC6A15 in various biological samples .

What emerging applications exist for studying SLC6A15 in the context of neuronal metabolism?

Emerging applications for studying SLC6A15 in neuronal metabolism leverage advanced technologies and interdisciplinary approaches:

• Metabolic Flux Analysis:

  • Use stable isotope-labeled BCAAs combined with mass spectrometry to track SLC6A15-mediated amino acid transport and subsequent metabolic pathways.

  • Correlate transport activity with metabolite profiles in neurons expressing different levels of SLC6A15 .

• Single-Cell Applications:

  • Combine single-cell RNA-seq with spatial transcriptomics to map SLC6A15 expression patterns with unprecedented resolution.

  • Use single-cell metabolomics to understand how SLC6A15 expression levels affect individual neuron metabolic signatures.

• Live Imaging Approaches:

  • Develop fluorescent BCAA analogs that can be transported by SLC6A15 for real-time visualization of transport activity.

  • Use genetically encoded FRET-based sensors to monitor BCAA levels in SLC6A15-expressing neurons.

• Integration with Electrophysiology:

  • Since SLC6A15 mediates electrogenic transport , combine patch-clamp electrophysiology with metabolic measurements to correlate transport activity with neuronal excitability.

  • Investigate how activity-dependent regulation of SLC6A15 affects neuronal energy metabolism.

• Therapeutic Targeting Strategies:

  • Use antibodies to validate the efficacy of compounds designed to modulate SLC6A15 activity.

  • Develop targeted approaches to enhance or inhibit SLC6A15 function in specific neuronal populations affected in neurological disorders .

• Protein Interaction Networks:

  • Apply proximity labeling methods with SLC6A15 antibodies to identify interaction partners that may regulate its function or localization.

  • Investigate how these interactions change under different metabolic states or in disease conditions.

These emerging applications represent cutting-edge approaches to understanding SLC6A15's role in neuronal metabolism and potential therapeutic interventions for related disorders .

What are the most reliable commercial sources for SLC6A15 antibodies and related research tools?

Based on the search results, several reliable commercial sources provide well-validated SLC6A15 antibodies and related research tools:

• Validated Antibody Providers:

  • Alomone Labs (Anti-SLC6A15 Antibody, catalog #AGT-016) - Validated for Western blot and immunohistochemistry in mouse and rat brain tissues .

  • Thermo Fisher Scientific (SLC6A15 Polyclonal Antibody, catalog #A304-476A and #PA5-36502) - Validated for Western blot in human cell lines and predicted to react with mouse, rat, bovine, and orangutan samples .

  • Bethyl Laboratories (manufacturers of antibodies distributed by Thermo Fisher) .

• Control Reagents:

  • SLC6A15 Blocking Peptide (catalog #BLP-GT016 from Alomone Labs) - Essential for specificity control experiments .

• Detection Kits:

  • ELISA Kits for SLC6A15 quantification (RK12309) - For quantitative measurement in human serum, plasma, cell culture supernatants, and tissue homogenates .

• Selection Criteria for Choosing the Appropriate Tool:

  • Application compatibility (Western blot, IHC, ELISA)

  • Species reactivity requirements

  • Epitope location (N-terminal, C-terminal, or internal)

  • Validation data availability

  • Lot-to-lot consistency

When selecting research tools, researchers should review the manufacturer's validation data, consider published literature using these reagents, and perform their own validation experiments to ensure reliability in their specific experimental systems .

How should I interpret and troubleshoot discrepancies in SLC6A15 expression data between different experimental approaches?

When facing discrepancies in SLC6A15 expression data between different experimental approaches, consider the following systematic troubleshooting framework:

• Methodological Differences Analysis:

  • Each detection method measures different aspects of expression:

    • Western blot: Protein levels in tissue/cell lysates

    • IHC: Spatial distribution and localization

    • ELISA: Quantitative protein levels in solution

    • qPCR/RNA-seq: mRNA expression levels

  • Consider whether discrepancies reflect methodological differences rather than true biological variation.

• Sample Preparation Considerations:

  • Membrane protein enrichment: SLC6A15 detection may be enhanced in membrane preparations compared to whole cell lysates .

  • Fixation effects: Different fixation methods may affect epitope accessibility in IHC .

  • RNA vs. protein extraction methods may yield different results due to post-transcriptional regulation.

• Antibody-Specific Factors:

  • Epitope differences: Antibodies targeting different regions of SLC6A15 may yield different results .

  • Cross-reactivity: Some antibodies may detect related transporters in the SLC6 family.

  • Validation status: Consider whether all antibodies used have been properly validated with appropriate controls .

• Biological Variability Assessment:

  • Regional expression differences: SLC6A15 is expressed in specific neuronal populations, so sampling differences may explain discrepancies .

  • Developmental stage: Expression may vary with age or developmental stage.

  • Health status: Pathological conditions may alter expression patterns.

• Resolution Strategy:

  • Perform side-by-side comparisons with standardized samples.

  • Include appropriate positive and negative controls for each method.

  • Use multiple antibodies targeting different epitopes.

  • Validate key findings with orthogonal approaches (e.g., mass spectrometry).

By systematically addressing these factors, researchers can resolve discrepancies and develop a more comprehensive understanding of SLC6A15 expression patterns .